David Moise
Family Medicine · Atlanta, GANPI 1245734367
Payments from drug & device makers
Across 130 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$460
- Lilly USA, LLC$358
- GSK$195
- Novartis$183
- Viiv Healthcare Company$149
- AstraZeneca$138
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,492100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $460 |
| Lilly USA, LLC | 21 | $358 |
| GSK | 11 | $195 |
| Novartis | 8 | $183 |
| Viiv Healthcare Company | 6 | $149 |
| AstraZeneca | 7 | $138 |
| Boehringer Ingelheim | 6 | $134 |
| Pfizer | 5 | $107 |
| Exact Sciences | 6 | $100 |
| AbbVie | 6 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Dynavax Technologies Corporation | 3 | $60 |
| Bayer | 3 | $57 |
| Currax Pharmaceuticals LLC | 4 | $57 |
| Amgen | 3 | $50 |
| Dexcom, Inc. | 2 | $43 |
| Merck | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Abbott | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
How this compares
$2,492 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $61,218 |
| JardianceEmpagliflozin | 43 | $56,666 |
| TrulicityDulaglutide | 33 | $53,588 |
| JanuviaSitagliptin Phosphate | 43 | $52,386 |
| EliquisApixaban | 43 | $51,307 |
| XareltoRivaroxaban | 29 | $31,197 |
| RybelsusSemaglutide | 14 | $30,112 |
| MounjaroTirzepatide | 21 | $28,569 |
| LinzessLinaclotide | 24 | $28,369 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $16,562 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $15,188 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,155 |
| MyrbetriqMirabegron | 16 | $12,050 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,944 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $460 | $91,33151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $358 | $82,15754 claims |
| MerckJanuvia, Janumet Xr | $34 | $67,57456 claims |
| Boehringer IngelheimJardiance | $134 | $56,66643 claims |
| PfizerEliquis | $107 | $51,30743 claims |
| AbbVieLinzess | $98 | $28,36924 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $195 | $17,07724 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $91 | $16,56220 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $12,05016 claims |
| AstraZenecaSymbicort | $138 | $6,94415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Atlanta
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Nadia CameronAtlanta$2.1M
- Otis PowellAtlanta$608K
- Thinh NguyenAtlanta$427K
- Patricia MarshAtlanta$175K
- Contessa MetcalfeAtlanta$157K
- Michelle EvansAtlanta$127K
- Mark TannerAtlanta$94K
- Ambar KulshreshthaAtlanta$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.